Erythropoietin misses mark in erectile function recovery after radical prostatectomy
Use of erythropoietin, a promising neurotrophic factor for neurogenic erectile dysfunction based on preclinical and retrospective data, has failed to improve recovery of erectile function in men undergoing radical prostatectomy for prostate cancer compared to placebo, a study has shown.
